Previous 10 | Next 10 |
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that while it...
2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...
2023-06-09 17:15:14 ET Gainers: PepGen ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital ( APLD ) +3% . Losers: Couchbase ( BASE ...
2023-06-09 14:37:00 ET Gainers: Blue Apron Holdings ( APRN ) +65% . Sientra ( SIEN ) +50% . ContraFect ( CFRX ) +43% . Global Indemnity ( GBLI ) +23% . Disc Medicine Opco ( IRON ) +21% . Olema Pharmaceuticals ( OLMA ) +...
2023-05-30 17:30:29 ET PepGen ( NASDAQ: PEPG ) on Tuesday said its investigational new drug (IND) application to treat a type of muscle wasting disease had been put on a clinical hold by the U.S. Food and Drug Administration (FDA). PEPG stock slumped 18.4% to $12.88 after ...
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company re...
2023-05-18 13:37:38 ET PepGen ( NASDAQ: PEPG ) said it received a no objection letter from Health Canada for an application to start a phase 2 trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51 skipping approach. The company expects to...
- CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51 in patients with mutations amenable to skipping exon 51 - - Initial data readout is expected mid-2024 - BOSTON, May 18, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. ...
2023-05-11 12:19:26 ET PepGen press release ( NASDAQ: PEPG ): Q1 GAAP EPS of -$0.69. Cash was $14.2 million as of March 31, 2023. For further details see: PepGen GAAP EPS of -$0.69
– Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51 multinational study expected to be initiated in the seco...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...